Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Reperfusion injury Stories

2010-11-02 07:00:00

PORTOLA VALLEY, Calif., Nov. 2, 2010 /PRNewswire/ -- Spectros Corporation presented new clinical results using tissue oxygen saturation with the T-Stat VLS Tissue Oximeter at the San Diego Convention Center during Anesthesiology 2010. This newly released data was presented during poster sessions entitled "Experimental Circulation: Ischemia and Reperfusion" and "Clinical Circulation: Pharmacology/Physiology", held at the American Society of Anesthesiologists (ASA 2010) on October 16, 2010...

2010-04-19 09:57:06

Liver surgery has become a safe procedure in the past years and is mainly done because of malignant tumors. A common strategy to reduce blood loss during surgery is to temporarily shut down the blood supply to the liver [pringle maneuver (PM)], which, however may be associated with severe hepatocellular injury and consequent enhanced morbidity. Many efforts were undertaken to overcome the deleterious effects of ischemia-reperfusion (I/R) injury of the liver caused by the PM. A new method of...

2010-02-10 09:14:14

Scientists report further progress in study of complement reaction Researchers have teased out the molecular process that can shut down a marauding, often deadly immune response that kills thousands each year who suffer battlefield casualties, heart attacks, strokes, automobile accidents and oxygen deprivation, according to an article published in the January edition of Molecular Immunology. The article provides additional detail about the enormously complex biomechanics of a reaction first...

2009-09-01 10:12:07

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half. AMI is caused by a sudden blockage of a coronary artery, one of the vessels supplying the heart muscle with oxygen and nutrients. Effective reperfusion therapy provides a timely and sustainable reopening of the blockage.The WHO MONICA* project showed that in European centers in the...

2009-08-26 08:47:25

It is known that I/R induces an inflammatory response deleterious to the organ involved but also to the system as a whole. Mesenteric ischemia occurs when the veins or arteries that supply blood to the intestine are obstructed. In transplants, the organ undergoes total (arterial and venous) I/R. Few available treatments exist. Greater knowledge of these conditions would aid in the search for new therapies. However, the precise nature of the response arises after venous, arterial or total...

2009-06-03 08:00:00

Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster presentation by Hani N. Sabbah, Ph.D., at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor Therapeutics, Inc. and conducted by Dr. Sabbah and colleagues at the...

2c43bcfaead83bbab32e094a829a1d451
2008-12-02 11:53:59

New class of lipids suggests new treatment approach for heart attacks Researchers have discovered one potential mechanism by which briefly cutting off, then restoring, blood flow to arteries prior to a heart attack lessens the damage caused, according to a study published today in the journal Cardiovascular Research. The new mechanism points to how future drugs could provide protection ahead of heart attacks and strokes for those at highest risk. In the nearer term, the work may help to...

2008-09-04 12:00:07

Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The Phase II clinical trial of FX06 (Fire study) in 234 patients with acute myocardial infarcts was completed in March 2008, with data indicating a statistically significant reduction in myocardial...

2008-09-02 06:00:06

Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany. The Phase II clinical trial of FX06 (F.I.R.E. study) in 234 patients with acute myocardial infarcts was completed in March...

2008-07-02 09:00:13

RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received a second $100,000 award from the State of Maryland Industrial Partnerships (MIPS) program after successful completion of the first year's research goals. The Company is working with the University of Maryland, Baltimore (UMB) to develop a novel pharmaceutical product specifically aimed at preventing reperfusion injury associated with cardiac ischemia (heart attack). RegeneRx is contributing...